Cytokinetics, Incorporated (CYTK)
NASDAQ · Healthcare
Cytokinetics, Incorporated Shareholder Equity 2009–2025
Cytokinetics, Incorporated annual shareholder equity history from 2010 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Cytokinetics, Incorporated shareholder equity as of December 31, 2025: -659.6M, a 387.27% increase year-over-year.
- Cytokinetics, Incorporated shareholder equity for 2025 were -659.6M, a 387.27% increase from 2024.
- Cytokinetics, Incorporated shareholder equity for 2024 were -135.4M, a 64.96% decrease from 2023.
- Cytokinetics, Incorporated shareholder equity for 2023 were -386.3M, a 258.04% increase from 2022.
- Cytokinetics, Incorporated shareholder equity for 2022 were -107.9M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Cytokinetics, Incorporated Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $-660 |
| 2024 | $-135 |
| 2023 | $-386 |
| 2022 | $-108 |
| 2021 | $244 |
| 2020 | $113 |
| 2019 | $-11 |
| 2018 | $26 |
| 2017 | $110 |
| 2016 | $94 |
| 2015 | $69 |
| 2014 | $92 |
| 2013 | $54 |
| 2012 | $70 |
| 2011 | $48 |
Cytokinetics, Incorporated Shareholder Equity — FAQ
Cytokinetics, Incorporated (CYTK) shareholder equity over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CYTK's shareholder equity history?
The chart and table above show Cytokinetics, Incorporated's shareholder equity by year and by quarter, including the growth rate.